The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 27501841.
- Also identified by PMC identifier 5106605.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The risk of infection among patients receiving immune checkpoint blockade is unknown. We retrospectively reviewed medical records of 740 patients with melanoma who received immune checkpoint blockers. Serious infection occurred in 54 patients (7.3%). The main risk factors were receipt of corticosteroids and/or infliximab.
Medical subject headings
- Adrenal Cortex Hormones
- Immunologic Factors
- Infections
- Infliximab
- Melanoma